Barclays on Monday downgraded biopharmaceutical company UCB (UCB.BR) to equal weight from overweight and decreased its price target to 300 euros from 310 euros.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)